Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas

https://doi.org/10.1016/0277-5379(87)90075-7Get rights and content

Abstract

Ifosfamide (IFOS) 5 g/m2 and its parent analog Cyclophosphamide (CYCLO) 1.5 g/m2 were studied in a randomized phase II study, accruing 171 patients with advanced soft tissue sarcoma. Both drugs were administered as 24 hr infusions, every 3 weeks, with comcomitant Mesna 400 mg/m2 i.v. bolus 4 hourly × 9 doses. Twenty-four patients were ineligible and 12 were not evaluable. The groups were well matched for age, previous chemotherapy (42% of the total) or radiotherapy, the presence of distant metastases and performance status, but there were more females (59% vs. 45%) in the IFOS arm.

Among the 68 evaluable patients receiving IFOS, there were 2 CR, 10 PR (overall response 18%), 27 SD and 29 PD. For CYCLO, the corresponding results in 67 patients were 1 CR, 4 PR (overall response 8%), 23 SD and 39 PD. Using the chi-square test the P values for response rate and linear trend were 0.13 and 0.04 respectively. Response rates were higher for females (20% vs. 5%, P = 0.01) and patients who had not received previous chemotherapy (19% vs. 4%, P = 0.01). Fourteen of the 17 responses came from a group of 43 females, who had not received previous chemotherapy, for whom the overall response rate was 37.5%. Remissions were noted in only 4 histological subtypes (centrally reviewed material), i.e., 5 of 17 synovial sarcomas, 7 of 13 mixed mesodermal sarcomas and 2 of 7 fibrosarcomas. One of the 31 leiomysarcomas responded to Cyclophosphamide. Durations of response did not differ significantly between the 2 arms—median 26, range 10–81 + weeks.

Leucopenia was significantly more severe on CYCLO, particularly in patients who had received previous chemotherapy (P = 0.007). Serious infections occurred in approx. 7% of patients with no difference between the two drugs, although there was one toxic death on CYCLO. Nausea and vomiting were significantly worse on IFOS and alopecia, related in extent to dose, was seen in both arms. Other side-effects, such as hematuria or rises in serum creatinine and encephalopathy, were infrequent and mild.

A higher response rate with less myelosuppression suggests that IFOS may have advantages over CYCLO in combination therapy.

References (43)

  • HM Pinedo et al.

    Chemotherapy of advanced soft tissue sarcoma in adults

    Cancer Treat Rev

    (1977)
  • WP Brade et al.

    Ifosfamide—pharmacology, safety and therapeutic potential

    Cancer Treat Rev

    (1985)
  • FR Eilber et al.

    Limb salvage for high grade soft tissue sarcomas: Experience at the University of California, Los Angeles

    Cancer Treat Symposia

    (1985)
  • WF Enneking et al.

    Adjuvant preoperative radiation therapy in treatment of soft tissue sarcoma: A preliminary report

    Cancer Treat Symposia

    (1985)
  • SA Rosenberg et al.

    Adjuvant chemotherapy for the treatment of extremity soft tissue sarcomas: Review of National Cancer Institute experience

    Cancer Treat Symposia

    (1985)
  • SA Rosenberg et al.

    Sarcomas of the soft tissue and bone

  • SA Rosenberg et al.

    The management of local and regional soft tissue sarcomas

  • FM Enzinger et al.

    Soft Tissue Tumors

    (1983)
  • G Bonadonna et al.

    Adriamycin (NSC-123127) studies at the Instituto Nazionale Tumori Milan

    Cancer Chemother Rep

    (1975)
  • VHC Bramwell et al.

    Bone and soft tissue sarcomas

  • VHC Bramwell et al.

    Bone and soft tissue sarcomas

  • VHC Bramwell et al.

    Bone and soft tissue sarcomas

  • G Bonadonna et al.

    Bone and soft tissue sarcomas

  • G Bonadonna et al.

    Bone and soft tissue sarcomas

  • G Bonadonna et al.

    Bone and soft tissue sarcomas

  • JA Gottlieb et al.

    Adriamycin (NSC-123127) used alone and in combination for soft tissue and bone sarcomas

    Cancer Chemother Rep

    (1975)
  • AE Giuliano et al.

    Failure of combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomas: implications for adjuvant studies

  • NB Bui et al.

    Analysis of a series of sixty soft tissue sarcomas in adults treated with a Cyclophosphamide-Vincristine-Adriamycin-Dacarbazine (CYVADIC) combination

    Cancer Chem Pharm

    (1985)
  • HM Pinedo et al.

    CYVADIC in advanced soft tissue sarcoma: a randomized study comparing two schedules

  • VHC Bramwell et al.

    Treatment of metastatic bone and soft tissue sarcomas

  • H Arnold

    Uber die chemie neuer zytostatisch wirksanser N-chlor-aethyl-phosphorsaur eesterdiamide

  • Cited by (222)

    View all citing articles on Scopus

    This investigation was supported by PHS grants numbers 2U10 CA 11488-14, 5U10 CA 11488-15. 3U10 CA 11488-15 and 2U10 CA 11488-16 awarded by the National Cancer Institute, DHHS, Bethesda, Maryland, USA.

    View full text